Pharma revenue target of ₹50-55 Cr for FY27
Management targets 50% growth in pharma sales from ₹34.3 Cr to ₹50-55 Cr in FY27.
MOLDTEKPACKAGING / guidance tracker
Keep management guidance in view.
Mold Tek Packaging · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin guidance of 42.5-43% for FY27
Management expects EBITDA margin to improve from 40.7% to 42.5-43% in FY27, driven by operational efficiencies and consolidation benefits.
Capex of ₹80-85 Cr for FY27
Capital expenditure to be reduced to ₹80-85 Cr in FY27, focused on brownfield expansions and pharma capacity.
Revenue growth of 13-15% in FY27
Management expects value growth of 13-15% in FY27, driven by paint recovery, pharma expansion, and food/FMCG growth.